Abstract: Apparatus for adding a beneficial agent to a liquid for drinking during oral administration includes a support structure extending transversely across an imperforate walled zone such as the upper end or neck of a bottle or vessel, or of a funnel-like adapter attached to the top of the vessel, with a retention pocket with liquid penetrable walls held by the support structure and comprising at least one beneficial agent secured therein whereby the beneficial agent is taken up in the liquid for drinking during or just prior to oral administration. The beneficial agent may be in either or both of controlled release dosage form or non-controlled release dosage form and may be one or more of nutrients, medicaments, probiotics, electrolytes, rehydration solutions and diagnostic agents, to which a flavoring agent may be added.

Abstract: An apparatus and method are disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply to a feeding tube delivering the modified liquid enteral nutritional product to the gastrointestinal tract of a patient. At least one beneficial agent not in controlled release dosage form in a useful, dose unit, amount, is disposed within a formulation chamber so as to be taken up in a liquid enteral nutritional product traversing the formulation chamber while feeding the modified nutritional product into the gastrointestinal tract of a patient. The beneficial additive(s) are selected from nutrients, medicaments, probiotics, or diagnostic agents, or mixtures thereof, each in a dosage form that is dispersible in the medium of the liquid enteral nutritional product in less than two hours.

Abstract: An apparatus is useful for dye marking a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. A formulation chamber, such as a drip chamber, is connectable to the supply container. At least one sustained release reservoir containing a physiologically acceptable marker dye is positioned within the formulation chamber, or if not, is included as part of a kit. The sustained release reservoir may be in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving material, or chopped hollow fibers having permeable walls. A liquid communication means connects the formulation chamber to the feeding tube of a patient. The marker dye may be a colorant dye or a fluorescing dye or a mixture thereof.

Abstract: A method for dye marking a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient includes the steps of: (1) providing apparatus such as a formulation chamber, e.g., a drip chamber, connectable to the supply container, with at least one sustained release reservoir containing a physiologically acceptable and dispersible marker dye positioned within the formulation chamber, and, liquid communication means connecting the formulation chamber to the feeding tube of a patient; (2) providing a supply container containing the nutritional product; (3) connecting the formulation chamber to the supply container and the liquid commmunication means to the feeding tube; and (4) flowing the dye-marked nutritional product through the apparatus and into the feeding tube.

Abstract: A method is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply container to a feeding tube delivering the nutritional product to the gastrointestinal tract of a patient. During enteral tube feeding the nutritional product passes through a formulation chamber, e.g., a drip chamber, having located therein at least one controlled release dosage form unit containing at least one beneficial agent. The beneficial agent may be selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, and any such together with a physiologically acceptable marker dye in controlled release dosage form and/or the same or different additional beneficial agent not in controlled release dosage form. Controlled release dosage forms may be of a conventional sustained release type or an osmotically driven delivery device.

Abstract: An apparatus is disclosed for modifying a liquid enteral nutritional product during delivery thereof from a supply thereof, such as a hangable container, to a feeding tube delivering the liquid enteral nutritional product to the gastrointestinal tract of a patient. The apparatus has at least one formulation chamber, such as a drip chamber, with at least one controlled release dosage form unit in the form of a coated tablet, osmotically driven device, coated capsule, microencapsulated microspheres, agglomerated molecular sieving type material, or a quantity of fine hollow permeable fibers located therein. The controlled release dosage form unit or units contain at least one beneficial agent selected from nutrients, medicaments, probiotics, or diagnostic agents or mixtures thereof, to any of which a physiologically acceptable marker dye in controlled release dosage form and/or the same or different beneficial agent not in controlled release dosage form may be added.

Abstract: An oral rehydration solution contains indigestible oligosaccharides. Diarrhea related dehydration requires fluid and electrolyte replacement. The primary etiology of antibiotic-associated diarrhea (also known as pseudomembranous colitis) has been recognized as Clostridium difficile. It is believed that the indigenous microflora of a healthy individual suppresses the normally present C. difficile. However, when the indigenous microflora are disrupted (e.g., during antibiotic treatment) overgrowth of C. difficile may occur causing diarrhea and colitis. Treatment of diarrhea related to C. difficile with rehydration therapy and antibiotics has proven effective, but many times relapse occurs. It has been suggested that normalization of the microflora will inhibit C. difficile relapse. Indigestible oligosaccharides have been shown to inhibit C. difficile infection.

Abstract: Apparatus for adding a beneficial agent to a liquid for drinking during oral administration includes a support structure extending transversely across an imperforate walled zone such as the upper end or neck of a bottle or vessel, or of a funnel-like adapter attached to the top of the vessel, with a retention pocket with liquid penetrable walls held by the support structure and comprising at least one beneficial agent secured therein whereby the beneficial agent is taken up in the liquid for drinking during or just prior to oral administration. The beneficial agent may be in either or both of controlled release dosage form or non-controlled release dosage form and may be one or more of nutrients, medicaments, probiotics, electrolytes, rehydration solutions and diagnostic agents, to which a flavoring agent may be added.